HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China

NCT06238284 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2024-02-02

No results posted yet for this study

Summary

This study aims to retrospectively analyze the HER2 expression of gynecological malignant tumors in Chongqing by immunohistochemical detection, and explore the correlation between HER2 level, therapy response and prognosis based on patient clinical information.

Conditions

Interventions

OTHER

no intervention

Since it is a retrospective study, no intervention is needed.

Sponsors & Collaborators

  • Chongqing University Cancer Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-26
Primary Completion
2024-03-31
Completion
2024-05-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06238284 on ClinicalTrials.gov